Evidence map›Paper›PMID 40444045›Full record

SynthesisFrontiers in pharmacology2025

Comparative effectiveness of semaglutide

Mohammad Amin Karimi, Mohammad Sadra Gholami Chahkand, Parisa Alsadat Dadkhah, Farzad Sheikhzadeh, Shayan Yaghoubi, Fatemeh Esmaeilpour Moallem, Mitra Sadat Deyhimi, Melika Arab Bafrani, Mehregan Shahrokhi, Amir Nasrollahizadeh

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mohammad Amin Karimi *School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mohammad Sadra Gholami Chahkand *Student Research Committee, Golestan University of Medical Sciences, Gorgan, Iran.
Parisa Alsadat DadkhahSchool of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Farzad SheikhzadehSchool of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Shayan YaghoubiStudent Research Committee, Faculty of Medicine, Islamic Azad University of Ardabil, Ardabil, Iran.
Fatemeh Esmaeilpour MoallemStudent Research Committee, Golestan University of Medical Sciences, Gorgan, Iran.
Mitra Sadat DeyhimiSchool of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Melika Arab BafraniSchool of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Mehregan ShahrokhiSchool of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Amir NasrollahizadehTehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study seeks to compare the effectiveness of Semaglutide compared to Liraglutide, Dulaglutide, or Tirzepatide. Additionally, it aims to investigate the implications of transitioning from Dulaglutide or Liraglutide to Semaglutide. Methods: We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials. Analyses were conducted using Review Manager (RevMan) version 5.4.1 and STATA 17. Results: The meta-analysis comprised 16 studies and 5,997 patients. Semaglutide significantly reduced hemoglobin A1c (HbA1c) levels compared to Liraglutide (0.56; 95% CI: 0.19-0.94; p < 0.001). However, no significant differences were observed between Semaglutide and Liraglutide in terms of fasting blood sugar (FBS), body mass index (BMI), and weight change. In comparison to Dulaglutide, Semaglutide displayed superior efficacy in reducing HbA1c levels (3.72; 95% CI: 0.02-7.41; p = 0.05) and FBS (2.66; 95% CI: 0.26-5.07; p = 0.03). However, no significant differences were found in weight and BMI change. Tirzepatide exhibited a notable advantage over Semaglutide in reducing HbA1c levels (-0.45; 95% CI: -0.88 to -0.02; p = 0.04). However, no clear superiority was observed for weight and FBS change. Transitions from Liraglutide to Semaglutide did not significantly impact HbA1c levels. However, weight loss (2.48; 95% CI: 0.45-4.51; p = 0.02) and reduced FBS levels (10.76; 95% CI: 0.55-20; p = 0.04) were observed. Transitioning from Dulaglutide to Semaglutide did not significantly affect HbA1c levels and weight change. Conclusion: While the precise source of heterogeneity remains elusive across most studies, analyses consistently demonstrate Semaglutide's superior efficacy compared to Liraglutide in reducing both HbA1c levels and weight. Moreover, it presents advantages over Dulaglutide, specifically in lowering FBS levels. However, Tirzepatide surpasses Semaglutide in its efficacy for reducing HbA1c levels.

Indexed as

dulaglutideGLP-1 (Glucagon-Like Peptide 1)HbA1cliraglutiderandomized controlled trialssemaglutidetirzepatidetype 2 diabetes mellitus

Identifiers

PMID40444045
PMCPMC12120964

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.